#USA #Prospera SCS #Lake Oswego, Oregon #BIOTRONIK Neuro #Embrace One

BIOTRONIK Neuro Launches Embrace One® Proactive Intelligence: A New Era for SCS Patients

In an exciting development for patients undergoing spinal cord stimulation (SCS) therapy, BIOTRONIK Neuro introduced its latest innovation, the Embrace One® Proactive Intelligence. This proprietary AI capability is designed to revolutionize the way care is administered to patients implanted with the Prospera® SCS system. The new tool emphasizes caring for patients proactively rather than reactively, helping both patients and healthcare providers navigate the complexities of pain management more effectively.

What is Embrace One® Proactive Intelligence?
Integrating a comprehensive technology pipeline, Embrace One® Proactive Intelligence collects and analyzes over 200 data points daily per patient through automatic and objective remote monitoring. This level of detailed data analysis allows the system to identify early signals that may indicate a patient's need for additional support or adjustments in therapy—often before patients recognize these needs themselves. The AI doesn't make clinical decisions; rather, it equips the Embrace One Care Team—composed of dedicated clinical specialists—with vital insights to prioritize outreach and follow-up care for patients.

Recent data presented at the American Society of Pain and Neuroscience (ASPN) annual meeting highlighted the effectiveness of this AI-driven model. In a pilot study involving 175 patients, the AI effectively flagged 188 behavioral patterns for the Care Team's review. Notably, 80.9% of patients responded positively to proactive outreach, resulting in tailored support including therapy optimization, remote reprogramming, and enhanced educational resources. This underscores the AI's potential in enhancing patient satisfaction and outcomes

Dr. David Dickerson from Endeavor Health in Chicago expressed the hope brought by this innovation: "Managing SCS therapy can be a challenge as patients may not always be aware of how subtle behavioral changes affect their pain relief. The Embrace One Proactive Intelligence supports our team in identifying those who need outreach to address issues before they escalate. This proactive approach truly enhances patient support."

Changing the Game in Pain Management
Historically, post-implant maintenance in SCS management has placed the onus on patients to recognize and report issues on their own. BIOTRONIK Neuro has changed that paradigm by being the first and only SCS manufacturer to offer a system that provides daily monitoring and remote programming capabilities. This represents a significant leapforward towards proactive management of spinal cord stimulation, combining continuous passive monitoring with personalized support.

The AI technology offers BIOTRONIK Neuro's clinical experts visibility into therapy performance and device data, allowing them to identify potential concerns before the patient experiences a reduction in pain relief. With the introduction of Embrace One Proactive Intelligence, the Care Team can now prioritize outreach effectively, ensuring that patients receive timely support tailored to their unique needs.

Why Remote Management Matters
For many patients dealing with chronic pain, spinal cord stimulation presents a medically validated option. By delivering electrical impulses, these systems help modulate nerve activity and can significantly alleviate pain signals. Traditionally, SCS systems necessitated multiple in-office visits for reprogramming, leading to delays in therapy, transportation issues, and heightened costs. Recommendations from industry experts increasingly advocate for SCS systems with robust remote monitoring to facilitate timely adjustments and optimize patient outcomes.

The Prospera SCS system stands out for its unique features, including its RESONANCE™ multiphase stimulation paradigm and the integration of remote monitoring with the proactive care provided by the Embrace One Care Team. This comprehensive approach allows for real-time adjustments to therapy, thus reducing the frequency and necessity of in-person consultations.

A Commitment to Patient-Centered Innovation
“At BIOTRONIK Neuro, we harness our rich dataset generated through remote monitoring to redefine how we support spinal cord stimulation patients,” said Holger Krumel, CEO of BIOTRONIK Group. “Our keen focus on marrying technology and patient needs drives us to continue pioneering advancements in therapeutic management of chronic pain.”

In summary, BIOTRONIK Neuro's Embrace One® Proactive Intelligence is set to make a significant impact on how SCS patients are monitored and cared for, ushering in an era of proactive healthcare that promotes higher engagement, better outcomes, and enhanced quality of life for those living with chronic pain.